# Chong Kin Liam

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/chong-kin-liam/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,416 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 32 |
| i10-index | 84 |
| Last Known Institution | University of Malaya |
| OpenAlex ID | https://openalex.org/A5055282224 |
| ORCID iD | 0000-0002-3639-9231 |
| Works | 297 |

## Researcher papers

- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study](https://scholariq.org/papers/first-line-erlotinib-versus-gemcitabine-cisplatin-in-patients-with-advanced-egfr/)
- [Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial](https://scholariq.org/papers/tepotinib-plus-gefitinib-in-patients-with-egfr-mutant-non-small-cell-lung-cancer/)
- [Lung Cancer Screening in Asia: An Expert Consensus Report](https://scholariq.org/papers/lung-cancer-screening-in-asia-an-expert-consensus-report/)
- [Attitudes and knowledge of newly diagnosed tuberculosis patients regarding the disease, and factors affecting treatment compliance.](https://scholariq.org/papers/attitudes-and-knowledge-of-newly-diagnosed-tuberculosis-patients-regarding-the/)
- [Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial](https://scholariq.org/papers/tepotinib-plus-osimertinib-in-patients-with-egfr-mutated-non-small-cell-lung/)
- [Time for a new language for asthma control: results from REALISE Asia](https://scholariq.org/papers/time-for-a-new-language-for-asthma-control-results-from-realise-asia/)
- [Common fears of patients undergoing bronchoscopy](https://scholariq.org/papers/common-fears-of-patients-undergoing-bronchoscopy/)
- [Causes of pleural exudates in a region with a high incidence of tuberculosis](https://scholariq.org/papers/causes-of-pleural-exudates-in-a-region-with-a-high-incidence-of-tuberculosis/)
- [A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease](https://scholariq.org/papers/a-randomized-placebo-controlled-phase-2-trial-of-cnto-6785-in-chronic/)
- [P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor](https://scholariq.org/papers/p1-15-15-real-world-experience-with-afatinib-after-failure-of-first-generation/)
- [Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure](https://scholariq.org/papers/resistance-mechanisms-causing-first-line-epidermal-growth-factor-receptor/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)

## Researcher university

- [University of Malaya](https://scholariq.org/institutions/university-of-malaya/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.